To determine the plasma baclofen concentrations of children undergoing continuous intrathecal baclofen infusion for treatment of cerebral spasticity, we assayed plasma samples from six children, 8 to 18 years of age, who were receiving intrathecal baclofen at constant rates of 77 to 400 μg/day. Plasma levels were at or below the limit of quantification (10 ng/mL) in all patients. (J Child Neurol 1999;14:408-409).
Get full access to this article
View all access options for this article.
References
1.
Price GW, Wilkin GP, Turnbull MJ, Boery NG: Are baclofen-sensitive GABAb receptors present on primary afferent terminals of the spinal cord? Nature1984;307:71-74.
2.
Bowery NG, Hill DR, Hudson AL, et al: Baclofen decreases neurotransmitter release in the mammalian CNS by an action at a noval GABA receptor. Nature1980;283:92-94.
3.
Knuttson E., Lindblom U., Martensson A.: Plasma and cerebrospinal fluid levels of baclofen (Lioresal) at optimal therapeutic responses in spastic paresis. J Neurol Sci1974;23:473-484.
4.
Müller H., Zierski J., Dralle D., et al: Pharmacokinetics of intrathecal baclofen, in Müller H, Zierski J, Penn RD (eds): Local-Spinal Therapy of SpasticityNew York , Springer-Verlag, 1988, pp 223-226.
5.
Hattab JR: Review of European clinical trials with baclofen, in Feldman RG, Young RRR, Koella WP (eds): Spasticity: Disordered Motor Control. Chicago, Yearbook Medical , 1980, pp 71-85.
6.
Albright AL: Baclofen in the treatment of cerebral palsy. J Child Neurol1996;11:77-83.
7.
Faigle JW, Keberle H., Degen PH: Chemistry and pharmacokinetics of baclofen, in Feldman RG, Young RRR, Koella WP (eds): Spasticity: Disordered Motor Control. Chicago, Yearbook Medical , 1980, 461-475.
8.
Wuis EW, Dirks Mjm, Vree TB, et al: Plasma and urinary excretion kinetics of oral baclofen in healthy subjects. Eur J Clin Pharmacol1989;17: 181-184.
9.
Penn RD, Kroin JS: Long-term intrathecal baclofen infusion for treatment of spasticity . J Neurosurg1987;66:181-185.
10.
Sallerin-Caute B., Lazorthes Y., Monsarrat B., et al: Baclofen levels after intrathecal administration in severe spasticity. Eur J Clin Pharmacol1991;40:363-365.
